Kangtai Bio's tetanus vaccine application accepted for review

Shenzhen Kangtai Biological Products (SZSE:300601) announced that its subsidiary, Beijing Minhai Biotechnology, has received notification that its application for marketing authorization for its adsorbed tetanus vaccine has been accepted by the National Medical Products Administration (NMPA). The vaccine, designed to prevent tetanus in susceptible individuals and newborns, has been assigned acceptance number CXSS2500049. While the acceptance is a positive step, the company cautions that the approval process includes technical review, clinical trial site inspection, and GMP compliance checks before the vaccine can be manufactured and sold. Kangtai Bio notes that the vaccine’s potential market launch will further enrich the company's product portfolio and strengthen its market position. The company has also stated the NMPA approval will not have any immediate impact on the company's results.